AIM: CCL22, mainly synthesized by monocyte-derived alternative (M2) macrophages, belongs to the CC family of chemokines and is involved in monocyte migration and recruitment. We have previously investigated CCL22 and histamine in atherosclerosis. Here, we investigated the hypothesis that CCL22 is involved in atherosclerosis, which is influenced by the differentiation of macrophage phenotypes via histamine. METHODS: CCL22 expression was investigated in human carotid arteries and coronary arteries with bare metal stents. Ligated carotid arteries of wild-type (C57BL/6J) and apolipoprotein E-deficient mice were also used as atherosclerotic models. The localization and expression of CCL22 and classical (M1)-like and M2-like macrophages in various human and mouse atherosclerotic lesions were investigated by immunohistochemical examination and quantitative real-time polymerase chain reaction. Histamine is expressed in atherosclerosis, and it induces inflammation and immunity. Human- and mice-derived monocytes and macrophages were used to examine the role of histamine in macrophage differentiation and CCL22-expression. Macrophages derived from histamine receptor 1 (H1R)- and 2 (H2R)-knockout (KO) mice were also examined. RESULTS: Atherosclerotic lesions showed a distribution of heterogeneous macrophage phenotypes with M1-like and M2-like macrophage dominant sites. CCL22 was distributed in sparse areas of vascular smooth muscle cells (VSMCs) and associated with M2-like macrophages. Moreover, H2R stimulation was associated with CCL22 expression via M2-like macrophage dominant differentiation. CONCLUSION: The expression of M1- or M2-like macrophages in atherosclerosis were observed to be dependent on the distribution of VSMCs owing to differences in causal stimuli and the switching of histamine receptors via Th1 or Th2 cytokines. These results suggest that CCL22 may control atherosclerosis.
AIM: CCL22, mainly synthesized by monocyte-derived alternative (M2) macrophages, belongs to the CC family of chemokines and is involved in monocyte migration and recruitment. We have previously investigated CCL22 and histamine in atherosclerosis. Here, we investigated the hypothesis that CCL22 is involved in atherosclerosis, which is influenced by the differentiation of macrophage phenotypes via histamine. METHODS:CCL22 expression was investigated in human carotid arteries and coronary arteries with bare metal stents. Ligated carotid arteries of wild-type (C57BL/6J) and apolipoprotein E-deficient mice were also used as atherosclerotic models. The localization and expression of CCL22 and classical (M1)-like and M2-like macrophages in various human and mouseatherosclerotic lesions were investigated by immunohistochemical examination and quantitative real-time polymerase chain reaction. Histamine is expressed in atherosclerosis, and it induces inflammation and immunity. Human- and mice-derived monocytes and macrophages were used to examine the role of histamine in macrophage differentiation and CCL22-expression. Macrophages derived from histamine receptor 1 (H1R)- and 2 (H2R)-knockout (KO) mice were also examined. RESULTS:Atherosclerotic lesions showed a distribution of heterogeneous macrophage phenotypes with M1-like and M2-like macrophage dominant sites. CCL22 was distributed in sparse areas of vascular smooth muscle cells (VSMCs) and associated with M2-like macrophages. Moreover, H2R stimulation was associated with CCL22 expression via M2-like macrophage dominant differentiation. CONCLUSION: The expression of M1- or M2-like macrophages in atherosclerosis were observed to be dependent on the distribution of VSMCs owing to differences in causal stimuli and the switching of histamine receptors via Th1 or Th2 cytokines. These results suggest that CCL22 may control atherosclerosis.
Authors: Puvi N Seshiah; Dean J Kereiakes; Sanjay S Vasudevan; Neuza Lopes; Baogen Y Su; Nicholas A Flavahan; Pascal J Goldschmidt-Clermont Journal: Circulation Date: 2002-01-15 Impact factor: 29.690
Authors: K Y Wang; N Arima; S Higuchi; S Shimajiri; A Tanimoto; Y Murata; T Hamada; Y Sasaguri Journal: FEBS Lett Date: 2000-05-19 Impact factor: 4.124
Authors: Darran G Cronshaw; Andreas Kouroumalis; Richard Parry; Adam Webb; Zarin Brown; Stephen G Ward Journal: J Leukoc Biol Date: 2006-04-13 Impact factor: 4.962
Authors: Vineesh V Raveendran; Donald D Smith; Xiaoyu Tan; Matthew E Sweeney; Gregory A Reed; Colleen A Flynn; Ossama W Tawfik; Ginger Milne; Kottarappat N Dileepan Journal: PLoS One Date: 2014-07-14 Impact factor: 3.240
Authors: Anna Kalinskaya; Oleg Dukhin; Anna Lebedeva; Elena Maryukhnich; Georgy Rusakovich; Daria Vorobyeva; Alexander Shpektor; Leonid Margolis; Elena Vasilieva Journal: Front Immunol Date: 2022-02-15 Impact factor: 7.561
Authors: Ele Ferrannini; Maria Laura Manca; Giulia Ferrannini; Felicita Andreotti; Daniele Andreini; Roberto Latini; Marco Magnoni; Stephen A Williams; Attilio Maseri; Aldo P Maggioni Journal: Front Cardiovasc Med Date: 2022-02-04
Authors: Emily Dookun; Anna Walaszczyk; Rachael Redgrave; Pawel Palmowski; Simon Tual-Chalot; Averina Suwana; James Chapman; Eduard Jirkovsky; Leticia Donastorg Sosa; Eleanor Gill; Oliver E Yausep; Yohan Santin; Jeanne Mialet-Perez; W Andrew Owens; David Grieve; Ioakim Spyridopoulos; Michael Taggart; Helen M Arthur; João F Passos; Gavin D Richardson Journal: Aging Cell Date: 2020-09-29 Impact factor: 9.304